A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone

Background Trifluridine, a thymidine-based chemotherapeutic, has limited bioavailability after clinical administration as it is rapidly degraded via thymidine phosphorylase. An oral combination tablet combines trifluridine with a potent thymidine phosphorylase inhibitor, tipiracil hydrochloride. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cleary, James M., Rosen, Lee S., Yoshida, Kenichiro, Rasco, Drew, Shapiro, Geoffrey I., Sun, Weijing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352756/
https://www.ncbi.nlm.nih.gov/pubmed/28111727
http://dx.doi.org/10.1007/s10637-016-0409-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352756/
https://www.ncbi.nlm.nih.gov/pubmed/28111727
http://dx.doi.org/10.1007/s10637-016-0409-9

Ejemplares similares